23andMe PGS Genetic Health Risk Report For BRCA1/BRCA2 (Selected Variants)

Cancer Predisposition Risk Assessment System

23andMe, Inc.

The following data is part of a De Novo classification by 23andme, Inc. with the FDA for 23andme Pgs Genetic Health Risk Report For Brca1/brca2 (selected Variants).

Pre-market Notification Details

DeNovo IDDEN170046
Device Name:23andMe PGS Genetic Health Risk Report For BRCA1/BRCA2 (Selected Variants)
ClassificationCancer Predisposition Risk Assessment System
Applicant 23andMe, Inc. 899 W.evelyn Ave Mountain View,  CA  94041
ContactLisa Charter
Product CodeQAZ  
CFR Regulation Number866.6090 [🔎]
DecisionGranted (DENG)
510(k) Premarket NotificationDevice Classification Under Section 513(f)(2)(de Novo) // Quick Links: Skip To Main Page Content Skip To Search Skip To Topics Menu Skip To Common Lin
Review Advisory BoardPathology
Classification AdvisoryMolecular Genetics
TypeDirect
Date Received2017-09-05
Decision Date2018-03-06
FDA ReviewDecision Summary
Reclassification Order:Reclassification Order

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.